INTRODUCING URGOSTART TREATMENT RANGE

URGOSTART PLUS HAS A UNIQUE MODE OF ACTION

UrgoStart Plus is composed of a unique TLC-NOSF Healing Matrix, which acts locally on the wound, on the two key factors significantly impairing wound healing healing:

BENEFITS 

  • With its unique TLC-NOSF* Healing Matrix (NOSF* impregnated in a TLC healing matrix) UrgoStart is the only local treatment proven to reduce healing time (1,2,3,4)

  • The sooner the UrgoStart treatment is initiated the better the healing outcomes for the patient (5)

  • UrgoStart treatment significantly improves patients' quality of life (2,3)

  • UrgoStart Plus acts from Day 1 to complete healing, whatever the wound healing stage, simplifying treatment for clinicians and saving costs for healthcare systems (6)

OTHER PROPERTIES 

  • Absorption of exudate

  • Creation and maintenance of a moist wound environment that promotes healing

  • Atraumatic & pain free removal

  • Respect of peri-wound skin

  • Very conformable and easy to reposition

INDICATIONS 

UrgoStart Plus is indicated for all stages (from the desloughing stage to complete healing) of exuding wounds including leg ulcers, diabetic foot ulcers, pressure ulcers, and long standing acute wounds. 

FACTOR 1

Inhibition of excess matrix metalloproteinases (MMPs)

FACTOR 2

Promotion of angiogenesis through migration and proliferation of endothelial cells 

URGOSTART IS AVAILABLE IN A FULL RANGE FOR YOUR PATIENTS

UrgoStart Plus Pad and UrgoStart Plus Border also contain poly-absorbent fibres which bind, trap and retain exudate, slough and debris present in the wound, keeping it clean throughout healing.

CONTRAINDICATIONS 

  • In order not to delay any optimal treatment, UrgoStart treatment range is contraindicated in cancerous wounds and fistula wounds which may reveal a deep abscess

  • Do not use when there is a known sensitivity to UrgoStart dressings

  • UrgoStart Plus Pad and UrgoStart Plus Border facilitate the management of minor bleeding wounds. However, they should not be used as a surgical sponge for heavily bleeding wound

*NOSF (Nano OligoSaccharide Factor) = KSOS (potassium sucrose octasulfate)

 

References

(1) Münter KC, Meaume S, Augustin M, Senet P, Kérihuel J.C. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. J Wound Care. 2017 Feb; 26 (Sup2): S4-S15. Erratum in: J Wound Care. 2017 Mar 2; 26(3): 153. (2) Meaume S. et al., Quality of life in patients with leg ulcers: results from CHALLENGE, a double-blind randomized controlled trial. Journal of Wound Care. 2017; 26 (7): 368-379. (3) Meaume S. et al., A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers. Wound Repair Regen. 2012; 20: 4, 500–511. (4) Edmonds M, Lázaro-Martínez JL, Alfayate-García JM, Martini J, Petit JM, Rayman G, Lobmann R, Uccioli L, Sauvadet A, Bohbot S, Kerihuel JC, Piaggesi A. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018 Mar;6(3):186-196. (5) Lazaro et al . Optimal wound closure of diabetic foot ulcers with early initiation of TLC-NOSF treatment: post-hoc analysis of Explorer.JWC VOL 28, Nº 6 , JUNE 2019. (6) An Economic Evaluation of UrgoStart® for Patients with Chronic Leg Ulcers in the United Kingdom. York University. Data on file. Urgo, 2011.

©2018 by UrgoStart Plus. Proudly created with Wix.com